Vitality Biopharma (VBIO) Starts Presentation at LD Micro 2017 Invitational
Vitality Biopharma (OTC: VBIO) focuses on the development of cannabinoids for the treatment of neurological and inflammatory disorders, such as inflammatory bowel disease and multiple sclerosis in the United States. Its products in the pipeline include Cannabosides - VITA-100 for gastrointestinal disorders, including inflammatory bowel disease and irritable bowel syndrome; Cannabosides - VITA-210 for muscle spasticity in multiple sclerosis and rare white matter disorders; and Cannabosides for epilepsy, schizophrenia, substance abuse, and Huntington’s disease. The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016. For more information, visit the company's…
